Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730390 | 0.90 | TSPO (0.47) | TSPO | |
| SCHEMBL19730399 | 0.85 | TSPO (0.53) | TSPOCYP3A4 | |
| SCHEMBL19730391 | 0.79 | — | — | |
| SCHEMBL19730397 | 0.79 | SLC2A2 (0.55) | TSPOCYP1A2CYP2C9CYP2C19SLC2A2 | |
| SCHEMBL19730396 | 0.75 | TSPO (0.50) | TSPOCYP3A4 | |
| SCHEMBL19730389 | 0.72 | GABRA2 (0.51) | TSPOSLC2A2 | |
| SCHEMBL19730400 | 0.70 | — | — | |
| SCHEMBL19730398 | 0.69 | GABRA2 (0.49) | TSPOSLC2A2 | |
| SCHEMBL8744762 | 0.69 | TP53 (0.56) | TP53MEN1KMT2A | |
| SCHEMBL11854802 | 0.69 | LCK (0.55) | TP53MEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | GRIN2A, GRIN1, GRIN2B | TP53 3072/4885TSPO 392/4885MEN1 1231/4885 |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | GRIN2A, GRIN1, GRIN2B | TP53 3072/4885TSPO 392/4885MEN1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.